A Phase 1 interventional study of Orforglipron and Simvastatin in Healthy, Obese and Overweight, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.
Among the 22 studies testing orforglipron in Obesity, this one is the 21st largest by enrollment, is one of 6 that started in 2024, is one of 6 in phase 1, and was the 9th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 10 more countries
Ages 6–17
Eli Lilly and Company · Sites in United States, Israel, Italy and 3 more countries
Ages 12–17
Eli Lilly and Company · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 324 across the 22 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 103rd largest by enrollment of the 117 interventional ones that give a count, is one of 20 that started in 2024, is one of 40 in phase 1, and was the 45th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
5 of the studies testing orforglipron in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972459Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies testing orforglipron in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that enters the bloodstream and how long it takes the body to eliminate them when administered orally in healthy overweight and obese participants. In addition, the effect of the orforglipron tablet on the amount of simvastatin that enters the bloodstream and how long it takes the body to eliminate it will be evaluated.
The study will also assess the effect of sodium bicarbonate when administered alone with simvastatin versus orforglipron capsule containing sodium bicarbonate administered with simvastatin. The safety and tolerability of orforglipron and information about any side effects experienced will be collected.
Study will be conducted in two parts, with part 1 and 2 lasting up to approximately 23 and 24 weeks each, including the screening period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single oral doses as follows:Day 1: 20 milligram(mg) simvastatin; Day 2: 0.25 mg digoxin; Day 7:20 mg simvastatin + 600 mg sodium bicarbonate; Day 8: 20 mg rosuvastatin; Day 10: 1000 mg acetaminophen; Day 12: 0.2 mg midazolam;Day 14: 1 mg Orforglipron, followed by 1000 mg acetaminophen administered 2 hours (±10 minutes) later (staggered); Day 15: 1 mg Orforglipron; Days 16-97: Orforglipron administered once daily with dose escalation every 14 days:1 mg (Days 16-27), 3 mg (Days 28-41),6 mg (Days 42-55),12 mg (Days 56-69),24 mg (Days 70-83),36 mg (Days 84-97). Days 98-110: 36 mg Orforglipron administered once daily with co administration as follows:Day 98: 20 mg simvastatin (simultaneous); Day 99: 0.25 mg digoxin (simultaneous); Day 104: 20 mg simvastatin (staggered); Day 105:20 mg rosuvastatin (simultaneous); Day 107: 1000 mg acetaminophen (staggered); Day 109:0.2 mg midazolam (simultaneous); Day 111: 20 mg Orforglipron tablet + 20 mg simvastatin (simultaneous).
Drug: Orforglipron · Drug: Simvastatin · Drug: Digoxin · Drug: Rosuvastatin · Drug: Acetaminophen · Drug: Midazolam · Drug: Sodium Bicarbonate
Participants received single oral doses as follows: Day 1: 20 mg Simvastatin; Day 2: 0.25 mg Digoxin; Day 7: 20 mg Simvastatin + 600 mg Sodium Bicarbonate; Day 9: 1 mg Orforglipron capsule; Days 10-90: Participants received orforglipron capsule orally QD for 12 weeks, beginning at 1 mg QD. The dose was escalated every 14 days as follows: 1 mg (Days 10-22), 3 mg (Days 23-36), 6 mg (Days 37-50), 12 mg (Days 51-64), 24 mg (Days 65-78), and 36 mg (Days 79-90). Participants continued 36 mg Orforglipron QD until Day 100, with co-administration of the following drugs; Day 93: 20 mg Simvastatin (simultaneous); Day 94: 0.25 mg Digoxin (simultaneous); Day 99: 20 mg Simvastatin administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing); Day 101: 20 mg Orforglipron tablet + 20 mg Simvastatin (simultaneous)
Drug: Orforglipron · Drug: Simvastatin · Drug: Digoxin · Drug: Sodium Bicarbonate
Administered orally.
Also known as: LY3502970
Administered orally.
Administered orally.
Administered orally.
Administered orally.
Administered orally.
Administered orally.
Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC[0-∞]) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.
Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours (h) post-dose; Day 98 (Cohort 1) and Day 93 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following staggered administration with or without Orforglipron capsule were reported in this outcome measure. Simvastatin was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 104 (Cohort 1) and Day 99 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without sodium bicarbonate administration were reported in this outcome measure.
Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 7 (Cohort 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
PK: AUC [0-∞] of Digoxin (Cohort 1 and 2)
Time frame: Day 2 (For Cohort 1 and 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose ; Day 99 (Cohort 1) and Day 94 (Cohort 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose
PK: AUC [0-∞] of Rosuvastatin (Cohort 1 Only)
Time frame: Day 8 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose; Day 105 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose
PK: AUC [0-∞] of Acetaminophen (Cohort 1 Only)
AUC \[0-∞\] of acetaminophen following staggered administration with or without either 1 mg or 36 mg Orforglipron capsule were reported in this outcome measure. Acetaminophen was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
Time frame: Day 10 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 14 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 107 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose
PK: AUC [0-∞] of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)
AUC \[0-∞\] of midazolam and its metabolite (1'-Hydroxymidazolam) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.
Time frame: Day 12 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose; Day 109 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose
PK: Maximum Observed Concentration (Cmax) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.
Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 98 (Cohort 1) and Day 93 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following staggered administration with or without Orforglipron capsule were reported in this outcome measure. Simvastatin was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 104 (Cohort 1) and Day 99 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without sodium bicarbonate administration were reported in this outcome measure.
Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 7 (Cohort 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
PK: Cmax of Digoxin (Cohorts 1 and 2)
Time frame: Day 2 (For Cohort 1 and 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose; Day 99 (Cohort 1) and Day 94 (Cohort 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose
PK: Cmax of Rosuvastatin (Cohort 1 Only)
Time frame: Day 8 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose; Day 105 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose
PK: Cmax of Acetaminophen (Cohort 1 Only)
Cmax of acetaminophen following staggered administration with or without either 1 mg or 36 mg Orforglipron capsule were reported in this outcome measure. Acetaminophen was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
Time frame: Day 10 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 14 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 107 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose
PK: Cmax of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)
Cmax of Midazolam and its metabolite (1'-Hydroxymidazolam) following simultaneous administration with or without Orforglipron capsule is reported in this outcome measure.
Time frame: Day 12 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose; Day 109 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron tablet were reported in this outcome measure.
Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 111 (Cohort 1) and Day 101 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron tablet were reported in this outcome measure.
Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 111 (Cohort 1) and Day 101 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
| Milestone | Cohort 1: Oral Drug Dosing With or Without Orforglipron Co-Administration | Cohort 2: Oral Drug Dosing With or Without Orforglipron Co-Administration |
|---|---|---|
| Started | 30 | 20 |
| Safety analysis population (received at least one dose of study drug) | 30 | 20 |
| Completed | 22 | 16 |
| Not completed | 8 | 4 |
| Withdrew: Adverse event | 6 | 1 |
| Withdrew: Sponsor decision | 0 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.
| Nanogram* hours per milliliter (ng*h/ml) | 20 mg Simvastatin Alone | Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin |
|---|---|---|
| Simvastatin | 22.1 ± 79.2 | 18.8 ± 84.3 |
| Metabolite- Simvastatin Acid | 13.6 ± 79.7 | 23.3 ± 74.2 |
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following staggered administration with or without Orforglipron capsule were reported in this outcome measure. Simvastatin was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
| ng*h/ml | 20 mg Simvastatin Alone | Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin |
|---|---|---|
| Simvastatin | 22.1 ± 79.2 | 20.1 ± 76.5 |
| Metabolite- Simvastatin Acid | 13.6 ± 79.7 | 30.2 ± 70.3 |
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without sodium bicarbonate administration were reported in this outcome measure.
| ng*h/ml | 20 mg Simvastatin Alone | 20 mg Simultaneous Simvastatin + 600 mg Sodium Bicarbonate |
|---|---|---|
| Simvastatin | 22.1 ± 79.2 | 20.3 ± 82.8 |
| Metabolite- Simvastatin Acid | 13.6 ± 79.7 | 14.0 ± 61.3 |
| ng*h/ml | 0.25 mg Digoxin Alone | Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin |
|---|---|---|
| PK: AUC [0-∞] of Digoxin (Cohort 1 and 2) | 18.8 ± 21.5 | 22.4 ± 26.5 |
| ng*h/ml | 20 mg Rosuvastatin Alone | Simultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin |
|---|---|---|
| PK: AUC [0-∞] of Rosuvastatin (Cohort 1 Only) | 116 ± 52.1 | 192 ± 60.1 |
AUC \[0-∞\] of acetaminophen following staggered administration with or without either 1 mg or 36 mg Orforglipron capsule were reported in this outcome measure. Acetaminophen was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
| ng*h/ml | 1000 mg Acetaminophen Alone | Staggered 1 mg Orforglipron Capsule + 1000 mg Acetaminophen | Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen |
|---|---|---|---|
| PK: AUC [0-∞] of Acetaminophen (Cohort 1 Only) | 59900 ± 37.2 | 52900 ± 39.0 | 73000 ± 64.3 |
AUC \[0-∞\] of midazolam and its metabolite (1'-Hydroxymidazolam) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.
| ng*h/ml | 0.2 mg Midazolam Alone | Simultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam |
|---|---|---|
| Midazolam | 3.82 ± 41.2 | 4.60 ± 47.3 |
| Metabolite- 1'-Hydroxymidazolam | 1.00 ± 43.2 | 1.34 ± 48.5 |
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.
| Nanogram per milliliter (ng/ml) | 20 mg Simvastatin Alone | Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin |
|---|---|---|
| Simvastatin | 4.68 ± 80.3 | 4.07 ± 89.1 |
| Metabolite-Simvastatin Acid | 1.25 ± 74.6 | 2.72 ± 84.8 |
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following staggered administration with or without Orforglipron capsule were reported in this outcome measure. Simvastatin was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
| ng/ml | 20 mg Simvastatin Alone | Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin |
|---|---|---|
| Simvastatin | 4.68 ± 80.3 | 3.34 ± 82.7 |
| Metabolite- Simvastatin Acid | 1.25 ± 74.6 | 2.94 ± 70.2 |
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without sodium bicarbonate administration were reported in this outcome measure.
| ng/ml | 20 mg Simvastatin Alone | 20 mg Simultaneous Simvastatin + 600 mg Sodium Bicarbonate |
|---|---|---|
| Simvastatin | 4.68 ± 80.3 | 4.62 ± 69.0 |
| Metabolite- Simvastatin Acid | 1.25 ± 74.6 | 1.23 ± 67.2 |
| ng/ml | 0.25 mg Digoxin Alone | Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin |
|---|---|---|
| PK: Cmax of Digoxin (Cohorts 1 and 2) | 1.02 ± 26.1 | 1.20 ± 46.1 |
| ng/ml | 20 mg Rosuvastatin Alone | Simultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin |
|---|---|---|
| PK: Cmax of Rosuvastatin (Cohort 1 Only) | 11.4 ± 69.8 | 14.2 ± 83.3 |
Cmax of acetaminophen following staggered administration with or without either 1 mg or 36 mg Orforglipron capsule were reported in this outcome measure. Acetaminophen was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
| ng/ml | 1000 mg Acetaminophen Alone | Staggered 1 mg Orforglipron Capsule + 1000 mg Acetaminophen | Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen |
|---|---|---|---|
| PK: Cmax of Acetaminophen (Cohort 1 Only) | 10800 ± 29.5 | 7760 ± 42.2 | 10800 ± 57.7 |
Cmax of Midazolam and its metabolite (1'-Hydroxymidazolam) following simultaneous administration with or without Orforglipron capsule is reported in this outcome measure.
| ng/ml | 0.2 mg Midazolam Alone | Simultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam |
|---|---|---|
| Midazolam | 1.23 ± 36.1 | 1.33 ± 43.8 |
| Metabolite- 1'-Hydroxymidazolam | 0.331 ± 46.8 | 0.357 ± 54.6 |
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron tablet were reported in this outcome measure.
| ng*h/ml | 20 mg Simvastatin Alone | Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin |
|---|---|---|
| Simvastatin | 22.1 ± 79.2 | 21.0 ± 82.2 |
| Metabolite- Simvastatin Acid | 13.6 ± 79.7 | 29.3 ± 72.0 |
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron tablet were reported in this outcome measure.
| ng/ml | 20 mg Simvastatin Alone | Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin |
|---|---|---|
| Simvastatin | 4.68 ± 80.3 | 3.78 ± 73.6 |
| Metabolite- Simvastatin Acid | 1.25 ± 74.6 | 3.00 ± 67.9 |
Collected over Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: 20 mg Simvastatin Alone (Day 1) | 0/30 (0%) | 0/30 (0%) | 2/30 (6.7%) |
| Cohort 1: 0.25 mg Digoxin Alone (Day 2) | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Cohort 1: 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7) | 0/28 (0%) | 0/28 (0%) | 0/28 (0%) |
| Cohort 1: 20 mg Rosuvastatin Alone (Day 8) | 0/28 (0%) | 0/28 (0%) | 0/28 (0%) |
| Cohort 1: 1000 mg Acetaminophen Alone (Day 10) | 0/27 (0%) | 0/27 (0%) | 1/27 (3.7%) |
| Cohort 1: 0.2 mg Midazolam Alone (Day 12) | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) |
| Cohort 1: Staggered 1 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 14) | 0/27 (0%) | 0/27 (0%) | 1/27 (3.7%) |
| Cohort 1: 1 mg Orforglipron Capsule QD (Day 15 to Day 27) | 0/27 (0%) | 0/27 (0%) | 4/27 (14.8%) |
| Cohort 1: 3 mg Orforglipron Capsule QD (Day 28 to Day 41) | 0/26 (0%) | 0/26 (0%) | 2/26 (7.7%) |
| Cohort 1: 6 mg Orforglipron Capsule QD (Day 42 to Day 55) | 0/26 (0%) | 0/26 (0%) | 5/26 (19.2%) |
| Cohort 1: 12 mg Orforglipron Capsule QD (Day 56 to Day 69) | 0/26 (0%) | 0/26 (0%) | 2/26 (7.7%) |
| Cohort 1: 24 mg Orforglipron Capsule QD (Day 70 to Day 83) | 0/26 (0%) | 0/26 (0%) | 2/26 (7.7%) |
| Cohort 1: 36 mg Orforglipron Capsule QD (Day 84 to Day 97) | 0/26 (0%) | 0/26 (0%) | 11/26 (42.3%) |
| Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 98) | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 99) | 0/22 (0%) | 0/22 (0%) | 2/22 (9.1%) |
| Cohort 1: 36 mg Orforglipron Capsule QD (Day 100 to Day 103) | 0/22 (0%) | 0/22 (0%) | 2/22 (9.1%) |
| Cohort 1: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 104) | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin (Day 105) | 0/22 (0%) | 0/22 (0%) | 2/22 (9.1%) |
| Cohort 1: 36 mg Orforglipron Capsule (Day 106) | 0/22 (0%) | 0/22 (0%) | 2/22 (9.1%) |
| Cohort 1: Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 107) | 0/22 (0%) | 0/22 (0%) | 1/22 (4.5%) |
| Cohort 1: 36 mg Orforglipron Capsule (Day 108) | 0/22 (0%) | 0/22 (0%) | 1/22 (4.5%) |
| Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam (Day 109) | 0/21 (0%) | 0/21 (0%) | 1/21 (4.8%) |
| Cohort 1: 36 mg Orforglipron Capsule (Day 110) | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Cohort 1: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 111) | 0/22 (0%) | 0/22 (0%) | 2/22 (9.1%) |
| Cohort 2: 20 mg Simvastatin Alone (Day 1) | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Cohort 2: 0.25 mg Digoxin Alone (Day 2) | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Cohort 2: Simultaneous 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7) | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Cohort 2: 1 mg Orforglipron Capsule QD (Day 9 to Day 22) | 0/20 (0%) | 0/20 (0%) | 9/20 (45%) |
| Cohort 2: 3 mg Orforglipron Capsule QD (Day 23 to Day 36) | 0/20 (0%) | 0/20 (0%) | 7/20 (35%) |
| Cohort 2: 6 mg Orforglipron Capsule QD (Day 37 to Day 50) | 0/19 (0%) | 0/19 (0%) | 6/19 (31.6%) |
| Cohort 2: 12 mg Orforglipron Capsule QD (Day 51 to Day 64) | 0/19 (0%) | 1/19 (5.3%) | 6/19 (31.6%) |
| Cohort 2: 24 mg Orforglipron Capsule QD (Day 65 to Day 78) | 0/18 (0%) | 0/18 (0%) | 4/18 (22.2%) |
| Cohort 2: 36 mg Orforglipron Capsule QD (Day 79 to Day 92) | 0/18 (0%) | 0/18 (0%) | 10/18 (55.6%) |
| Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 93) | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 94) | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Cohort 2: 36 mg Orforglipron Capsule QD (Day 95 to Day 98) | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Cohort 2: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 99) | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Cohort 2: 36 mg Orforglipron Capsule (Day 100) | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Cohort 2: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 101) | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| Event | Cohort 1: 20 mg Simvastatin Alone (Day 1) | Cohort 1: 0.25 mg Digoxin Alone (Day 2) | Cohort 1: 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7) | Cohort 1: 20 mg Rosuvastatin Alone (Day 8) | Cohort 1: 1000 mg Acetaminophen Alone (Day 10) | Cohort 1: 0.2 mg Midazolam Alone (Day 12) | Cohort 1: Staggered 1 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 14) | Cohort 1: 1 mg Orforglipron Capsule QD (Day 15 to Day 27) | Cohort 1: 3 mg Orforglipron Capsule QD (Day 28 to Day 41) | Cohort 1: 6 mg Orforglipron Capsule QD (Day 42 to Day 55) | Cohort 1: 12 mg Orforglipron Capsule QD (Day 56 to Day 69) | Cohort 1: 24 mg Orforglipron Capsule QD (Day 70 to Day 83) | Cohort 1: 36 mg Orforglipron Capsule QD (Day 84 to Day 97) | Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 98) | Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 99) | Cohort 1: 36 mg Orforglipron Capsule QD (Day 100 to Day 103) | Cohort 1: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 104) | Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin (Day 105) | Cohort 1: 36 mg Orforglipron Capsule (Day 106) | Cohort 1: Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 107) | Cohort 1: 36 mg Orforglipron Capsule (Day 108) | Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam (Day 109) | Cohort 1: 36 mg Orforglipron Capsule (Day 110) | Cohort 1: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 111) | Cohort 2: 20 mg Simvastatin Alone (Day 1) | Cohort 2: 0.25 mg Digoxin Alone (Day 2) | Cohort 2: Simultaneous 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7) | Cohort 2: 1 mg Orforglipron Capsule QD (Day 9 to Day 22) | Cohort 2: 3 mg Orforglipron Capsule QD (Day 23 to Day 36) | Cohort 2: 6 mg Orforglipron Capsule QD (Day 37 to Day 50) | Cohort 2: 12 mg Orforglipron Capsule QD (Day 51 to Day 64) | Cohort 2: 24 mg Orforglipron Capsule QD (Day 65 to Day 78) | Cohort 2: 36 mg Orforglipron Capsule QD (Day 79 to Day 92) | Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 93) | Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 94) | Cohort 2: 36 mg Orforglipron Capsule QD (Day 95 to Day 98) | Cohort 2: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 99) | Cohort 2: 36 mg Orforglipron Capsule (Day 100) | Cohort 2: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 101) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SchwannomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 0/30 | 0/28 | 0/28 | 0/27 | 0/27 | 0/27 | 0/27 | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/21 | 0/22 | 0/22 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/19 | 1/19 | 0/18 | 0/18 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 |
| Event | Cohort 1: 20 mg Simvastatin Alone (Day 1) | Cohort 1: 0.25 mg Digoxin Alone (Day 2) | Cohort 1: 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7) | Cohort 1: 20 mg Rosuvastatin Alone (Day 8) | Cohort 1: 1000 mg Acetaminophen Alone (Day 10) | Cohort 1: 0.2 mg Midazolam Alone (Day 12) | Cohort 1: Staggered 1 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 14) | Cohort 1: 1 mg Orforglipron Capsule QD (Day 15 to Day 27) | Cohort 1: 3 mg Orforglipron Capsule QD (Day 28 to Day 41) | Cohort 1: 6 mg Orforglipron Capsule QD (Day 42 to Day 55) | Cohort 1: 12 mg Orforglipron Capsule QD (Day 56 to Day 69) | Cohort 1: 24 mg Orforglipron Capsule QD (Day 70 to Day 83) | Cohort 1: 36 mg Orforglipron Capsule QD (Day 84 to Day 97) | Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 98) | Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 99) | Cohort 1: 36 mg Orforglipron Capsule QD (Day 100 to Day 103) | Cohort 1: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 104) | Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin (Day 105) | Cohort 1: 36 mg Orforglipron Capsule (Day 106) | Cohort 1: Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 107) | Cohort 1: 36 mg Orforglipron Capsule (Day 108) | Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam (Day 109) | Cohort 1: 36 mg Orforglipron Capsule (Day 110) | Cohort 1: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 111) | Cohort 2: 20 mg Simvastatin Alone (Day 1) | Cohort 2: 0.25 mg Digoxin Alone (Day 2) | Cohort 2: Simultaneous 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7) | Cohort 2: 1 mg Orforglipron Capsule QD (Day 9 to Day 22) | Cohort 2: 3 mg Orforglipron Capsule QD (Day 23 to Day 36) | Cohort 2: 6 mg Orforglipron Capsule QD (Day 37 to Day 50) | Cohort 2: 12 mg Orforglipron Capsule QD (Day 51 to Day 64) | Cohort 2: 24 mg Orforglipron Capsule QD (Day 65 to Day 78) | Cohort 2: 36 mg Orforglipron Capsule QD (Day 79 to Day 92) | Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 93) | Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 94) | Cohort 2: 36 mg Orforglipron Capsule QD (Day 95 to Day 98) | Cohort 2: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 99) | Cohort 2: 36 mg Orforglipron Capsule (Day 100) | Cohort 2: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 101) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/30 | 0/30 | 0/28 | 0/28 | 0/27 | 0/27 | 0/27 | 0/27 | 0/26 | 0/26 | 0/26 | 0/26 | 6/26 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 1/22 | 0/22 | 0/22 | 0/21 | 0/22 | 0/22 | 0/20 | 0/20 | 0/20 | 1/20 | 1/20 | 1/19 | 1/19 | 1/18 | 4/18 | 0/16 | 1/16 | 1/16 | 0/16 | 0/16 | 0/16 |
| FatigueGeneral disorders | 0/30 | 0/30 | 0/28 | 0/28 | 0/27 | 0/27 | 0/27 | 1/27 | 1/26 | 0/26 | 1/26 | 0/26 | 0/26 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/21 | 0/22 | 0/22 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 3/19 | 0/19 | 0/18 | 1/18 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 |
| EructationGastrointestinal disorders | 0/30 | 0/30 | 0/28 | 0/28 | 0/27 | 0/27 | 0/27 | 0/27 | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/21 | 0/22 | 0/22 | 0/20 | 0/20 | 0/20 | 3/20 | 1/20 | 2/19 | 0/19 | 1/18 | 0/18 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 |
| Alanine aminotransferase increasedInvestigations | 0/30 | 0/30 | 0/28 | 0/28 | 0/27 | 0/27 | 0/27 | 0/27 | 0/26 | 0/26 | 1/26 | 0/26 | 1/26 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/21 | 0/22 | 2/22 | 0/20 | 0/20 | 0/20 | 0/20 | 1/20 | 0/19 | 0/19 | 0/18 | 0/18 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 2/16 |
| Aspartate aminotransferase increasedInvestigations | 0/30 | 0/30 | 0/28 | 0/28 | 0/27 | 0/27 | 0/27 | 0/27 | 0/26 | 0/26 | 1/26 | 0/26 | 1/26 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/21 | 0/22 | 2/22 | 0/20 | 0/20 | 0/20 | 0/20 | 1/20 | 0/19 | 0/19 | 0/18 | 0/18 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 2/16 |
| NauseaGastrointestinal disorders | 0/30 | 0/30 | 0/28 | 0/28 | 1/27 | 0/27 | 0/27 | 0/27 | 1/26 | 2/26 | 0/26 | 0/26 | 3/26 | 0/22 | 2/22 | 0/22 | 0/22 | 0/22 | 0/22 | 1/22 | 0/22 | 0/21 | 0/22 | 0/22 | 1/20 | 0/20 | 0/20 | 2/20 | 2/20 | 1/19 | 1/19 | 0/18 | 1/18 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 |
| HeadacheNervous system disorders | 2/30 | 0/30 | 0/28 | 0/28 | 0/27 | 0/27 | 1/27 | 0/27 | 0/26 | 1/26 | 0/26 | 1/26 | 2/26 | 0/22 | 0/22 | 0/22 | 0/22 | 1/22 | 0/22 | 1/22 | 0/22 | 1/21 | 0/22 | 0/22 | 0/20 | 0/20 | 0/20 | 2/20 | 0/20 | 2/19 | 1/19 | 0/18 | 0/18 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 1/16 |
| Abdominal painGastrointestinal disorders | 0/30 | 0/30 | 0/28 | 0/28 | 0/27 | 0/27 | 0/27 | 0/27 | 0/26 | 0/26 | 0/26 | 1/26 | 2/26 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/21 | 0/22 | 0/22 | 0/20 | 0/20 | 0/20 | 0/20 | 2/20 | 0/19 | 0/19 | 0/18 | 0/18 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 |
| Decreased appetiteMetabolism and nutrition disorders | 0/30 | 0/30 | 0/28 | 0/28 | 0/27 | 0/27 | 0/27 | 0/27 | 0/26 | 0/26 | 0/26 | 0/26 | 0/26 | 0/22 | 0/22 | 0/22 | 0/22 | 1/22 | 0/22 | 0/22 | 0/22 | 0/21 | 0/22 | 0/22 | 0/20 | 0/20 | 0/20 | 2/20 | 0/20 | 1/19 | 0/19 | 0/18 | 0/18 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 |
| DyspepsiaGastrointestinal disorders | 0/30 | 0/30 | 0/28 | 0/28 | 0/27 | 0/27 | 0/27 | 0/27 | 0/26 | 2/26 | 0/26 | 0/26 | 0/26 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/21 | 0/22 | 0/22 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 1/19 | 1/19 | 0/18 | 0/18 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 |
All enrolled population.
| Age, Continuous(Years) | Cohort 1: Oral Drug Dosing With or Without Orforglipron | Cohort 2: Oral Drug Dosing With or Without Orforglipron | Total |
|---|---|---|---|
| Mean | 45.5 ± 12.80 | 42.9 ± 12.17 | 44.4 ± 12.49 |
| Sex: Female, Male(Participants) | Cohort 1: Oral Drug Dosing With or Without Orforglipron | Cohort 2: Oral Drug Dosing With or Without Orforglipron | Total |
|---|---|---|---|
| Female | 21 | 13 | 34 |
| Male | 9 | 7 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Oral Drug Dosing With or Without Orforglipron | Cohort 2: Oral Drug Dosing With or Without Orforglipron | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 7 | 19 |
| Not Hispanic or Latino | 18 | 13 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Oral Drug Dosing With or Without Orforglipron | Cohort 2: Oral Drug Dosing With or Without Orforglipron | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 4 | 13 |
| White | 20 | 15 | 35 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1: Oral Drug Dosing With or Without Orforglipron | Cohort 2: Oral Drug Dosing With or Without Orforglipron | Total |
|---|---|---|---|
| United States | 30 | 20 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2024 to primary completion in Jul 2024, 6 months.
Results were first posted in May 2026, 1 year 10 months after primary completion.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 6 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Orforglipron · Simvastatin · Digoxin · Acetaminophen